XERS compared with ARVN: revenue, margins and what each company keeps, and the suppliers and customers both name

XERSXeris Biopharma Holdings, Inc.

Mkt capRevenueRevenue

ARVNArvinas, Inc.

Mkt capRevenueRevenue

Compare

XERSXeris Biopharma Holdings, Inc.

ARVNArvinas, Inc.

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Earnings history

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Earnings history

last 4 reports each · paired by recencyMethod ›

XERS

1 of 4at or beyond implied

Reportimpliedrealized× implied

Q3 FY26±15.0%▲+25.05%×1.67

Q2 FY26±14.3%▼−9.25%×0.65

May 7 '26±12.7%▲+4.08%×0.32

Q1 FY26±21.8%▼−1.63%×0.07

ARVN

1 of 4at or beyond implied

Reportimpliedrealized× implied

Q3 FY26±29.4%▼−5.72%×0.19

Q2 FY26±9.0%▲+11.66%×1.30

= impliedXERS realized, solidARVN realized, hatchedOne scale, both sides: full bar = 30%× = |realized| ÷ impliedSource: market data

May 12 '26

±8.5%

▼−0.93%

×0.11

Q1 FY26±22.1%▲+0.57%×0.03

XERSXeris Biopharma Holdings, Inc.

15.20▲+16.17%· post 15.12

Mkt cap$2.8BRevenue$107MQ3 FY26Revenue$292MFY25

ARVNArvinas, Inc.

6.41▼−2.14%· post 6.41

ClosedNov 6 '26

Mkt cap$419.8MRevenue$500,000Q3 FY26Revenue$263MFY25

Compare

ClosedNov 6 '26

XERSXeris Biopharma Holdings, Inc.

ARVNArvinas, Inc.

15.20▲+16.17%post 15.12

Price

6.41▼−2.14%post 6.41

$2.8B

Mkt cap

$419.8M

Q3 FY26$107M

Revenue

$500,000Q3 FY26

FY25$292M

Revenue

$263MFY25

XERS15.20▲+16.17%vsARVN6.41▼−2.14%ClosedNov 6 '26